ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced that the Resynchronization Therapy In Normal QRS (RethinQ) Trial, which studied a subgroup of heart failure patients, most of whom are currently not indicated for cardiac resynchronization therapy (CRT), did not reach its primary effectiveness endpoint of improved oxygen consumption at peak exercise (peak VO2). While there was a statistically significant improvement in NYHA class, a secondary endpoint, there was no improvement in quality-of-life, 6-minute walk or echocardiographic measures in the patients who received CRT.
